Islets of Hope

Volume 2, Issue 1:  January 2006

islets of hope home buttondiabetes law buttonchildren with diabetes, right to educationaffiliate products and servicesdiabetes news buttonclincal trials, research, studies buttonamazon diabetes books and magazines

Last Updated:  To be published:  January 1, 2005            

Headline News
Drug Recalls & Developments
Stem Cell Research
  Diabetes Technology  *  Diabetes Legislation  *  Diabetes Events
        Islet Cell Transplanation  *  
General Diabetes Studies

diabetes news headlines archive button

Last Month's Paper:

Product Watch: Frio Products Leave Consumers out in the Cold

Editorial: The Great Label Debate:  I'm Not Diabetic, I just Have Diabetes

Clinical Trial Update: Arkansas

Lily Cautions that Cymbalta May Increase Risk for Liver Damage

Two New Possibiliites in Stem Cell Research

Warning Issues About Abbott Glucose Meters

Inhaled Insulin Approved by FDA Approval

Stem Cell Institute Opens in Mission Bay, CA

Islets of News Editorial Feature

The Great Label Debate:  Are you a diabetic?  Or do you just have diabetes?  

  Howard Wolpert
Smart Pumping
Smart Pumping integrates pump  technology with the physical and psychological aspects of diabetes care, and helps patients adopt the insulin pump into their self-care regime.

This book combines a compre- hensive medical approach toward intensive diabetes management and pump therapy with a patient-centered appreciation of the real-life challenges and frustrations.


  Product Review

Sharper Image's CarbTracker Scale  This scale is the "weigh" to go for counting carbs and other food nutrients.

 Drug Warnings

Lilly Cautions that Cymbalta may increase risk for liver damage: October 18, 2005.  ST. LOUIS (MD Consult) - "On October 17, 2005, Eli Lilly and the US Food and Drug Administration (FDA) notified health care professionals of a revision to the Precautions/Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain..."

 Diabetes Drugs Approved in 2005

Increlex (mecasermin), a drug from Tercicia was approved fby the FDA in August 2005 for the treatment of growth failure in pediatric patients.  Increlex contains recombinant-DNA- engineered human insulin-like growth factor-1 (rhIGF-1).  It is designed to replace natural IGF-1 in pediatric patients who are deficient, promoting normal statural growth.

ActoPlus Met - "Takeda Pharm- aceutical Co. has obtained U.S. FDA Administration approval for a new combination of insulin sensitizing drugs, Actoplus Met is a combination of Actos and Metformin."  Associated Press, August 30, 2005.

Byettaa (exenatide) - Derived from a compound found in the saliva of the Gila monster, a large lizard native to the southwestern US, mimicks the function of GLP-1, the drug helps more strongly activate this pathway to improve glycemic control and is indicated for type 2 treatment.

Symlin (pramlintide)  - A synthetic form of the hormone amylin normally produced by the beta cells along with insulin.  Amylin, insulin, and a third hormone called glucagon all work together to maintain normal glucose levels.  Studies show a modest improvement in A1C levels for individuals adding pramlintide to their diabetes care routine.


Diabetes Drugs May
Cause Blindness
Health Canada; Wednesday, December 21, 2005 Posted at 9:59 PM EST; Canadian Press

"Toronto - Two drugs used to treat Type 2 diabetes have been found to cause or worsen a serious vision impairment known as macular edema, Health Canada warned Wednesday.

"The advisory was released after GlaxoSmithKline Inc., the manufacturer of Avandia and Avandamet, informed Health Canada of reports that some diabetics on the drugs had developed the eye condition or had a pre-existing case worsen."  Read Full Article

Johnson & Johnson to Acquire Animas Corp.

NEW YORK (AP) Health products maker Johnson & Johnson (JNJ) said Friday that it has agreed to acquire Animas (PUMP), an insulin delivery company, for about $518 million to capitalize on the growing demand for diabetes treatment.

The acquisition will give Johnson & Johnson immediate entry in the fast-growing insulin delivery pump market, the company said.

J&J, based in New Brunswick, N.J., said it would pay $24.50 for each Animas share, a 35% premium to Animas' Thursday closing stock price on the Nasdaq.

Tamiflu Approved to Prevent Flu in Kids Under 12

But it's not a substitute for a flu shot, FDA says

FRIDAY, Dec. 23 (HealthDay News) -- The Roche Pharmaceuticals drug Tamiflu (oseltamivir phosphate) has been approved by the U.S. Food and Drug Administration to prevent flu in children 1 to 12 years of age. While it's the first drug approved to prevent both the A and B types of flu in children, Tamiflu is not a substitute for the annual flu vaccine, the FDA warned.

In a study of 222 children, the drug reduced the incidence of flu from 17 percent among those who received no preventive treatment to 3 percent in the group that received Tamiflu. The benefit in children mirrored results from previous trials involving adults, the FDA said. Read the Article


Prescription Price
Disclosure Act

Chicago A new Illinois law effective January 1, 2006, ensures that consumers can comparison shop to find the lowest price for their prescription medications. Based on that law, Attorney General Lisa Madigan today urged Illinoisans to take advantage of the new law to help lower skyrocketing monthly prescription costs.

12/29/05; Read Press Release


Lipid files FDA Application for Cholesterol Filter

Lipid Sciences Inc. said Thursday it applied for Food and Drug Administration approval to test a device that removes cholesterol from a patient's blood.

Pleasanton-based Lipid (NASDAQ: LIPD) wants to run a clinical trial of the device, called the Plasma Delipidation System-2, which treats human blood plasma to remove HDL cholesterol after that blood has been pumped out of the patient. The treated blood is then returned to the patient's body.

If approved, the trial will be run at the Washington Hospital Center in Washington, D.C. and will enroll 30 male and female patients between ages 18 and 75 who are suffering from coronary heart disease.

Lipid hopes to begin the trial in the first quarter of 2006.


Clinical Trial Update
Clinical Trials Resource List

Studies Recruiting Patients


Contact Us  |  About IOH  |  Our Mission  |  Elizabeth's Story  |  About the Founder  |  Join IOH  |  How To Help  |  Advertise with Us  | |  Site Index  |


                                      insulin pumps for underinsured mellitus patients

Page Updated 12/09/2005